Scientists say they have made a breakthrough designing a vaccine against all 20 known types of flu.
Flu mutates and the current annual jab is updated to ensure the best match for the sort circulating but would probably not protect against new pandemic types.
The new vaccine triggered high levels of antibodies, in tests on ferrets and mice, that could fight a broad range. The antigens it contains - safe copies of recognisable bits of all 20 known subtypes of influenza A and B viruses - can teach the immune system how to fight them and, hopefully, any new strain that could spark a pandemic, the researchers say, in the journal"The idea here is to have a vaccine that will give people a baseline level of immune memory to diverse flu strains," Dr Scott Hensley, one of the scientists behind the work, at the University of Pennsylvania, said.
"They are very promising and, although they suggest a protective capacity against all subtypes of influenza viruses, we cannot be sure until clinical trials in volunteers are done." Estanislao Nistal, a virologist at San Pablo University, said: "All of this implies the potential for an easily and rapidly constructed universal vaccine that could be of great use in the event of a pandemic outbreak of a novel influenza virus."
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Frontiers | Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patientsEctonucleotidases modulate inflammatory responses by balancing extracellular ATP and adenosine (ADO) and might be involved in COVID-19 immunopathogenesis. Here, we explored the contribution of extracellular nucleotides metabolism to COVID-19 severity in mild and severe cases of the disease. We verified that the gene expression of ectonucleotidases is reduced in the whole blood of patients with COVID-19 and is negatively correlated to CRP plasma levels, an inflammatory marker of disease severity. In line with these findings, COVID-19 patients present higher ATP levels in plasma and reduced levels of ADO when compared to healthy controls. Cell type-specific analysis revealed higher frequencies of CD39+ T cells in severely ill patients, while CD4+ and CD8+ expressing CD73 are reduced in this same group. The frequency of B cells CD39+CD73+ is also decreased during acute COVID-19. Interestingly, B cells from COVID-19 patients showed a reduced capacity to hydrolyze ATP into ADP and ADO. Furthermore, impaired expression of ADO receptors and a compromised activation of its signaling pathway is observed in COVID-19 patients. The presence of ADO in vitro, however, suppressed inflammatory responses triggered in patients’ cells. In summary, our findings support the idea that alterations in the metabolism of extracellular purines contribute to immune dysregulation during COVID-19, possibly favoring disease severity, and suggest that ADO may be a therapeutic approach for the disease.
Read more »
Near-Record Number Of Covid Infections Weigh On Oil Demand In China | OilPrice.comChina is registering near-record numbers of new Covid infections daily—close to the April 2022 peak when the financial center Shanghai was under lockdown for weeks
Read more »
The Lex Newsletter: China will soothe zero-Covid misery with Korean media\n\t\t\tLet our global subject matter experts broaden your perspective with timely insights and opinions you\n\t\t\tcan’t find anywhere else.\n\t\t
Read more »
Covid warning issued for age group as long-term sign could impact life every dayA new study has revealed that Covid-19 can cause short-term memory loss.
Read more »
England stars not allowed to see stunning Wags at World Cup over Covid fearsENGLAND players could meet their families after Friday’s United States match – but it depends on Covid rates in Qatar. Manager Gareth Southgate is hoping that the 26-man squad could have a pr…
Read more »
Bivalent mRNA vaccines could enhance protective efficacy against COVID-19A new study presents evidence suggestive of restored or increased efficacy from changing the formulation of COVID-19 vaccines to a bivalent one.
Read more »